Abstract
L-Asparaginase is an established component of acute leukemia therapy. PEG-asparaginase (PEGAsp), Escheria coli L-asparaginase linked to polyethylene glycol (PEG), is a common first-line formulation. However, PEGAsp hypersensitivity occurs in 10-15% of patients, with the PEG component most commonly suggested [PCA1] antigenic culprit. Because mRNA COVID-19 vaccines contain PEG, albeit of a different molecular weight, administration safety in patients with prior PEGAsp hypersensitivity has been questioned.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
